Advice

following an abbreviated submission:

glecaprevir/pibrentasvir (MaviretĀ®) is accepted for use within NHSScotland.

Indication under review: treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 to <18 years.

SMC has previously accepted glecaprevir/pibrentasvir for the treatment of chronic HCV infection in adults.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of glecaprevir/pibrentasvir. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

Download detailed advice364KB (PDF)

Download

Medicine details

Medicine name:
glecaprevir/pibrentasvir (Maviret)
SMC ID:
SMC2214
Indication:

For treatment of chronic hepatitis C virus (HCV) infection in adults and in adolescents aged 12 to <18 years.

Pharmaceutical company
AbbVie Ltd
BNF chapter
Infections
Submission type
Abbreviated
Status
Accepted
Date advice published:
11 November 2019